Merck's Oral Antiviral Molnupiravir Receives First Global Approval in the UK for High-Risk COVID-19 Patients
MSD
Pharmaceutical R&D and Manufacturer
Ridgeback
Biotechnology Company
Medicines and Healthcare products Regulatory Agency
The MHRA is an executive agency of the UK Department of Health and Social Care, responsible for ensuring that medicines and medical devices work effectively and are safe and reliable. Established in 2003 through the merger of the Medicines Control Agency and the Medical Devices Agency, the organization employs more than 1,300 staff members.
According to reports, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved molnupiravir, an oral COVID-19 drug developed by Merck (MRK.US) and Ridgeback Biotherapeutics.
On November 4, MSD/Ridgeback announcedThe Medicines and Healthcare products Regulatory Agency (MHRA) has approved molnupiravir (MK-4482, EIDD-2801) for marketing in the UK,Indicated for the treatment of adult patients with mild to moderate COVID-19 who are at high risk of progression to severe COVID-19, including hospitalization. Molnupiravir is the world's first approved treatment forAdult mild to moderateCOVID-19oral antiviral drug, these patients tested positive for SARS-CoV-2 on a diagnostic test and had at least one risk factor for progression to severe disease.